Clinical Trial

Baricitinib in CPPD - the BAPTIST Study

Study acronym: BAPTIST
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 10, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this clinical trial is to determine if baricitinib is effective in treating calcium pyrophosphate deposition disease (CPPD) in adults. The primary objective is to assess its impact on joint inflammation. The key questions the study seeks to answer are: * Can baricitinib reduce inflammation in affected joints? * Will baricitinib lead to changes in ultrasound findings, such as calcium crystal deposition and synovitis? Researchers will compare baricitinib to other treatments, including methylprednisolone, colchicine, hydroxychloroquine, and methotrexate with folic acid, for managing CPPD.
Trial Details
NCT Number NCT06768294
Lead Sponsor I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Conditions Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
Enrollment 32 participants
Start Date 2025-01
Primary Completion 2026-06 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-10